Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B.
about
Management of HBV and HBV/HDV-Associated Liver CirrhosisKASL clinical practice guidelines: management of chronic hepatitis BNatural history of chronic hepatitis B virus infection from infancy to adult life - the mechanism of inflammation triggering and long-term impactsAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Current hepatitis B treatment guidelines and future research directions.Prognostic values of fluctuations in serum levels of alanine transaminase in inactive carrier state of HBV infection.HBV genotype C is independently associated with cirrhosis in community-based populationPresence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients.Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?Approach to clinical syndrome of jaundice and encephalopathy in tropicsKASL Clinical Practice Guidelines: Management of chronic hepatitis B.Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010.Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients.DNA-guided hepatitis B treatment, viral load is essential, but not sufficientHepatobiliary Quiz Answers - 18 (2016).Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.Diagnosis of hepatitis B virus infection through serological and virological markers.HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B.Prevalence of hepatitis B virus genotype B in Vietnamese patients with chronic hepatitis B.New perspectives of biomarkers for the management of chronic hepatitis B.Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection.Treating Immune-tolerant Hepatitis B.HBV: Do I treat my immunotolerant patients?Role of hepatitis E infection in acute on chronic liver failure in Egyptian patients.Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C.Predictors of hepatitis B e antigen-negative hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood.Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion.Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion.Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection.Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion.Effect of serum hepatitis B surface antigen levels on predicting the clinical outcomes of chronic hepatitis B infection: A meta-analysis.High risk of hepatitis B virus reactivation in nucleos(t)ide analogue-induced hepatitis B e antigen seroconverters older than 40 years.Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study.Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters.Hepatitis B virus infection in clustering of infection in families with unfavorable prognoses in northwest China.The Possible Role of TLR2 in Chronic Hepatitis B Patients with Precore Mutation.Viral load, genotypes, and mutants in hepatitis B virus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma.Characterization of hepatitis B virus molecular genotypes in Chongqing and quantitative serological markers in patients during natural phases of chronic hepatitis B infection.
P2860
Q26740323-FAF46A5F-6353-4E8C-A77B-D6B208D5294CQ26752475-0DB05793-693F-4F10-B373-2D2357452647Q26781165-577DCB8E-EC0F-45A9-A3A8-E56BC93007FCQ30391932-BCBC6A22-914F-4E8F-845A-FFF44C1363B6Q30487002-39BBD6F7-4342-4773-9154-F91532BB6344Q33580037-3D8EEA00-E57A-4B08-BC5B-2CBC269E95B8Q33596550-1FD4947F-3431-445D-8B8C-F555F7FB6FA1Q34252292-18739F04-1ED3-46D5-BA3F-646CBF55D10CQ34462246-5DD5092A-4B8A-4833-B8D0-25016EB1FF94Q34779745-C378A54D-96CA-46EA-A719-EAA0E265E575Q35642864-8446222E-5C42-48B7-944A-817633469262Q36153966-ACF67138-C1C1-4915-963F-79DE3E57BDFAQ36177134-785731A1-7D66-49EF-A2C6-A058F4E71D34Q36973383-A6EF2F5E-E99F-4480-AFD5-7D5538A6E09BQ36981346-42DB95B6-CECC-45D3-BEC2-D71DCA217141Q37122325-FA9992B3-5691-4A06-AC0F-91B92FAF9DE2Q37131606-A81EF94C-1D6D-4F00-8AA6-CD20481894C3Q37278241-888528A9-06E2-4CD6-9201-C4C238F7505AQ37345962-5C878600-901D-4865-841C-BA21464B41EAQ37356782-C04BFD09-728F-4302-83FA-25C71901D596Q37356801-203FD214-2331-42F6-8246-480542C363A9Q37606546-03ADB4CA-D72A-4F2C-A890-6920ED71A44FQ37855732-172F8A79-1BFD-4507-BA52-A05932B94E35Q38271430-3D9B262B-6963-406A-B19C-57521FF7303BQ38685592-62819BC5-ADD2-4DA3-B1BF-BC3F1AB33BBCQ38985669-66C71430-A78A-448C-83A1-C19B24F765ABQ39474534-39A1A2EF-A55A-4932-83BF-1B42CEA32BA0Q40519686-E939E59D-3463-4D11-9D49-668951EAB716Q40707285-AF337966-C859-445F-BF13-DFA26F8A6B2DQ40707293-2BE61888-CF43-4981-9133-3C39401137ECQ41412291-DAE1368B-FDC6-4145-AD5A-09A59FF28BD5Q41556990-272D7A0F-770E-49CE-B0EC-B00E6E75BB30Q41684870-4F6FC4E3-9227-49A7-85A1-73CFFAF09621Q42217489-416228DB-9E25-48B2-B63B-41B622FD6B4BQ42217913-E1062182-26F2-421D-818A-08288C12B972Q42245695-C4732752-7A6F-4A51-A921-103EFE1C4C00Q42251541-3A0CFB6B-784F-4E95-9EAA-1C38E6703D7FQ42258017-6FAA4FD2-4237-4F90-B37D-DD149213A92CQ42492943-E94451AA-E54A-4B54-B63B-B9208C211641Q43553454-A4529C2F-1F1C-4DD1-9A62-97DD49627BFC
P2860
Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Predictive factors for reactiv ...... ersion in chronic hepatitis B.
@ast
Predictive factors for reactiv ...... ersion in chronic hepatitis B.
@en
Predictive factors for reactiv ...... ersion in chronic hepatitis B.
@nl
type
label
Predictive factors for reactiv ...... ersion in chronic hepatitis B.
@ast
Predictive factors for reactiv ...... ersion in chronic hepatitis B.
@en
Predictive factors for reactiv ...... ersion in chronic hepatitis B.
@nl
prefLabel
Predictive factors for reactiv ...... ersion in chronic hepatitis B.
@ast
Predictive factors for reactiv ...... ersion in chronic hepatitis B.
@en
Predictive factors for reactiv ...... ersion in chronic hepatitis B.
@nl
P1433
P1476
Predictive factors for reactiv ...... ersion in chronic hepatitis B.
@en
P2093
Chia-Ming Chu
P304
P356
10.1053/J.GASTRO.2007.08.039
P407
P50
P577
2007-08-21T00:00:00Z